Prognostic impact of tumour-associated B cells and plasma cells in epithelial ovarian cancer.

B cell regulation of the anti-tumor response and role in carcinogenesis. J Immunother Cancer (2016) 0.86

Detailed resolution analysis reveals spatial T cell heterogeneity in the invasive margin of colorectal cancer liver metastases associated with improved survival. Oncoimmunology (2017) 0.75

Identification of immunoglobulin V(D)J recombinations in solid tumor specimen exome files: Evidence for high level B-cell infiltrates in breast cancer. Hum Vaccin Immunother (2017) 0.75

Prognostic impact of tumour-associated B cells and plasma cells in oesophageal and gastric adenocarcinoma. J Gastrointest Oncol (2016) 0.75

B cell regulation in cancer and anti-tumor immunity. Cell Mol Immunol (2017) 0.75

Hallmarks of cancer: the next generation. Cell (2011) 140.01

Immunity, inflammation, and cancer. Cell (2010) 28.27

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med (2011) 26.90

Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med (2003) 16.62

The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer (2012) 10.90

Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A (2005) 10.89

A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest (2007) 8.54

Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci U S A (2007) 7.49

The humoral immune system has a key prognostic impact in node-negative breast cancer. Cancer Res (2008) 5.69

The Malmo Diet and Cancer Study. Design and feasibility. J Intern Med (1993) 5.35

Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol (2012) 4.44

Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression. Breast Cancer Res (2007) 3.76

Possible role of ovarian epithelial inflammation in ovarian cancer. J Natl Cancer Inst (1999) 3.64

Tumour immunity: effector response to tumour and role of the microenvironment. Lancet (2008) 2.94

Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis. Gynecol Oncol (2011) 2.67

Immune surveillance: a balance between protumor and antitumor immunity. Curr Opin Genet Dev (2008) 2.62

Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors. PLoS One (2009) 2.36

A comprehensive analysis of human gene expression profiles identifies stromal immunoglobulin κ C as a compatible prognostic marker in human solid tumors. Clin Cancer Res (2012) 1.83

Heparan sulfate proteoglycans and cancer. Br J Cancer (2001) 1.75

Population-attributable risk of coronary heart disease risk factors during long-term follow-up: the Malmö Preventive Project. J Intern Med (2006) 1.68

CD20+ tumor-infiltrating lymphocytes have an atypical CD27- memory phenotype and together with CD8+ T cells promote favorable prognosis in ovarian cancer. Clin Cancer Res (2012) 1.64

Expression of the RNA-binding protein RBM3 is associated with a favourable prognosis and cisplatin sensitivity in epithelial ovarian cancer. J Transl Med (2010) 1.51

B cells regulate macrophage phenotype and response to chemotherapy in squamous carcinomas. Cancer Cell (2014) 1.43

The impact of T-cell immunity on ovarian cancer outcomes. Immunol Rev (2008) 1.43

Combination chemotherapy and IL-15 administration induce permanent tumor regression in a mouse lung tumor model: NK and T cell-mediated effects antagonized by B cells. J Immunol (1998) 1.20

RBM3-regulated genes promote DNA integrity and affect clinical outcome in epithelial ovarian cancer. Transl Oncol (2011) 1.16

The role of polymeric immunoglobulin receptor in inflammation-induced tumor metastasis of human hepatocellular carcinoma. J Natl Cancer Inst (2011) 1.14

Distribution and clinical significance of heparan sulfate proteoglycans in ovarian cancer. Clin Cancer Res (2004) 1.13

The relationship between lymphocyte subsets and clinico-pathological determinants of survival in patients with primary operable invasive ductal breast cancer. Br J Cancer (2013) 1.00

Syndecan-1 expression--a novel prognostic marker in pancreatic cancer. Oncology (2005) 0.99

Expression of the global regulator SATB1 is an independent factor of poor prognosis in high grade epithelial ovarian cancer. J Ovarian Res (2012) 0.98

The prognostic relevance of tumour-infiltrating plasma cells and immunoglobulin kappa C indicates an important role of the humoral immune response in non-small cell lung cancer. Cancer Lett (2013) 0.98

Expression and prognostic significance of the polymeric immunoglobulin receptor in esophageal and gastric adenocarcinoma. J Transl Med (2014) 0.91

Clinical significance of syndecan-1 and versican expression in human epithelial ovarian cancer. Oncol Rep (2010) 0.91

Alterations in polymeric immunoglobulin receptor expression and secretory component levels in bladder carcinoma. Urol Res (1991) 0.90

Tumor-Infiltrating Plasma Cells Are Associated with Tertiary Lymphoid Structures, Cytolytic T-Cell Responses, and Superior Prognosis in Ovarian Cancer. Clin Cancer Res (2016) 0.86

Reduced expression of the polymeric immunoglobulin receptor in pancreatic and periampullary adenocarcinoma signifies tumour progression and poor prognosis. PLoS One (2014) 0.86

Syndecan-1 overexpression is associated with nonluminal subtypes and poor prognosis in advanced breast cancer. Am J Clin Pathol (2013) 0.85

Clinicopathological correlates and prognostic significance of KRAS mutation status in a pooled prospective cohort of epithelial ovarian cancer. Diagn Pathol (2013) 0.85

Shed Syndecan-1 is involved in chemotherapy resistance via the EGFR pathway in colorectal cancer. Br J Cancer (2014) 0.84

Expression and prognostic significance of the polymeric immunoglobulin receptor in epithelial ovarian cancer. J Ovarian Res (2014) 0.84

Discovery of dachshund 2 protein as a novel biomarker of poor prognosis in epithelial ovarian cancer. J Ovarian Res (2012) 0.84

Immunoglobulin kappa chain as an immunologic biomarker of prognosis and chemotherapy response in solid tumors. Oncoimmunology (2012) 0.82

Evaluation of BCL-6, CD10, CD138 and MUM-1 expression in diffuse large B-cell lymphoma patients: CD138 is a marker of poor prognosis. Asian Pac J Cancer Prev (2012) 0.81

Syndecan-1 antigen, a promising new target for triple-negative breast cancer immuno-PET and radioimmunotherapy. A preclinical study on MDA-MB-468 xenograft tumors. EJNMMI Res (2011) 0.81

Reduced syndecan-1 expression stimulates heparin-binding growth factor-mediated invasion in ovarian cancer cells in a urokinase-independent mechanism. Oncol Rep (2005) 0.78

Prognostic impact of tumour-infiltrating B cells and plasma cells in colorectal cancer. Int J Cancer (2016) 0.80